Peripheral Nervous System
1 Small Fiber Neuropathy
Small fiber neuropathy (SFN) affects thinly myelinated A-delta fibers and unmyelinated C fibers, which mediate pain, temperature, and autonomic functions. SFN has emerged as a significant finding in ME/CFS.
1.1 Skin Biopsy Findings
Punch skin biopsies with intraepidermal nerve fiber density (IENFD) measurement represent the gold standard for SFN diagnosis:
- Reduced IENFD: Multiple studies report decreased nerve fiber density in ME/CFS patients (Oaklander et al. 2013) (Grayston et al. 2019)
- Correlation with symptoms: Lower IENFD correlates with pain severity and autonomic dysfunction
- Distal predominance: Typical length-dependent pattern with greater abnormalities in feet than thighs
- Prevalence: Estimates range from 30–80% of ME/CFS patients meeting criteria for SFN, with the wide range reflecting variability in diagnostic methods (skin biopsy IENFD vs sudomotor testing), disease definition heterogeneity, and whether fibromyalgia-overlapping cohorts are included (Oaklander et al. 2022) (Grayston et al. 2019). Oaklander et al. (Oaklander et al. 2013) found 41% of fibromyalgia patients (overlapping with ME/CFS) had reduced IENFD diagnostic for SFN. A meta-analysis by Grayston et al. (Grayston et al. 2019) reported 49% pooled prevalence (95% CI: 38-60%) of small fiber pathology in fibromyalgia across 8 studies
1.2 Autonomic Testing
Quantitative sudomotor axon reflex testing (QSART) and related methods assess small fiber autonomic function:
- Reduced sweat output: Indicating sudomotor dysfunction
- Abnormal sweat gland innervation: On skin biopsy analysis
- Correlation with orthostatic intolerance: SFN may contribute to autonomic dysregulation
1.3 Pain Mechanisms
SFN may explain chronic pain in ME/CFS through:
- Neuropathic pain: Burning, tingling, electric shock sensations
- Allodynia: Pain from normally non-painful stimuli
- Hyperalgesia: Exaggerated pain responses
- Central sensitization: Peripheral nerve damage may trigger central pain amplification
1.4 Potential Causes of SFN in ME/CFS
- Autoimmune mechanisms (ganglioside antibodies, sodium channel antibodies)
- IgG-mediated DRG targeting: passive transfer experiments demonstrate that purified IgG from long COVID patients accumulates in lumbar DRG and sensitises nociceptive neurons (Mignolet et al. 2026) (Goebel et al. 2021) (see GPCR Autoantibody-Based Autonomic Phenotyping Defines Treatable ME/CFS Subtypes)
- Metabolic dysfunction (mitochondrial, oxidative stress)
- Chronic inflammation
- Microvascular abnormalities affecting nerve blood supply
- Direct viral damage (in post-infectious cases) — SARS-CoV-2 RNA and monocyte infiltration have been demonstrated within the vagus nerve itself (Woo et al. 2023)
1.5 Post-COVID SFN: ME/CFS Overlap and IVIG Response
McAlpine et al. (2024) conducted a retrospective case-control study of 16 patients with new-onset SFN following COVID-19, recruited from the Yale NeuroCOVID Clinic (McAlpine et al. 2024). Key findings:
- 92% of post-COVID SFN patients met the post-exertional malaise criterion for ME/CFS, suggesting post-COVID SFN is frequently a ME/CFS-overlapping phenotype rather than an isolated neuropathy
- SFN was predominantly non-length-dependent—implying DRG-level rather than axon-length-dependent pathology, mechanistically consistent with IgG accumulation at DRG somata reported in passive transfer studies
- Invasive cardiopulmonary exercise testing (\(n=7\)) confirmed neurovascular dysregulation consistent with autonomic small fiber involvement
- IVIG response: 9/9 treated patients improved versus 3/7 untreated (\(p=0.02\)), supporting an autoimmune mechanism and suggesting the IgG-DRG axis may be therapeutically actionable in this subgroup
Study: (retrospective case-control, Class III evidence, \(n=16\); Yale NeuroCOVID Clinic; certainty: 0.52, partially replicated).
The co-occurrence of non-length-dependent SFN, ME/CFS criteria fulfilment, and IVIG responsiveness in post-COVID patients is consistent with a DRG-level autoimmune mechanism in which circulating IgG binds sensory neuron somata, causing functional sensitisation and eventual fiber loss measurable by IENFD reduction. The passive transfer triad (Goebel 2021, Mignolet 2026, Chen 2026; GPCR Autoantibody-Based Autonomic Phenotyping Defines Treatable ME/CFS Subtypes) provides direct experimental support for IgG accumulation at DRG in this disease context.
Testable prediction: Post-COVID ME/CFS patients with non-length-dependent SFN on skin biopsy should show reduced IENFD correlating with DRG-binding IgG titres. IVIG response should be greater in non-length-dependent versus length-dependent SFN subtypes.
Treatment implication: If this hypothesis is confirmed, IVIG and immunoadsorption would be the most mechanistically rational interventions for post-COVID ME/CFS patients with documented non-length-dependent SFN. Non-length-dependent pattern on skin biopsy may eventually serve as a stratification biomarker for autoimmune etiology and IVIG candidacy — pending prospective validation.
Limitation: McAlpine 2024 is retrospective (\(n=16\), Class III). The specific DRG antigens targeted by IgG in post-COVID SFN are unknown. IVIG effect may reflect immune modulation rather than specific autoantibody removal. Independent replication needed.
Study: (mechanistic synthesis; McAlpine 2024 + passive transfer triad; certainty: 0.40, hypothesis plausible but DRG antigens uncharacterised).
Certainty: 0.30. Dorsal root ganglion (DRG) neurons are unmyelinated, highly metabolically active, and depend on intact mitochondrial function for their large cytoplasmic volume and long axonal projections. They are therefore disproportionately vulnerable to ISR-driven energy failure (Costa-Mattioli and Walter 2020). HHV-6 viral miRNA (miR-aU14) has been detected in dorsal root ganglia of ME/CFS post-mortem tissue (Kasimir et al. 2022), establishing viral neuroinvasion of this exact compartment. If HHV-6 reactivation in DRGs activates the ISR via miR-aU14–DRP1 fragmentation (Hennig et al. 2022), the resulting mitochondrial failure would preferentially manifest as sensory dysfunction in small fibres (A-delta and C fibres), producing the small fibre neuropathy documented in ~49% of ME/CFS patients.
This ISR-DRG mechanism would be parallel to, and potentially additive with, the IgG-mediated DRG targeting mechanism (IgG-Mediated Non-Length-Dependent SFN: DRG-Level Autoimmune Mechanism): viral ISR damage and IgG sensitisation could independently or cooperatively drive IENFD reduction and sensory symptoms. The ISR mechanism predicts that SFN severity would correlate with HHV-6 reactivation markers (miR-aU14 in plasma exosomes, anti-dUTPase IgG) rather than with serum IgG autoantibody titres.
Testable prediction: ME/CFS patients with SFN (reduced IENFD) will show higher HHV-6 dUTPase IgG titres and higher plasma miR-aU14 levels than ME/CFS patients without SFN. Skin biopsy from SFN-positive ME/CFS patients will show ATF4 immunoreactivity in surviving DRG-derived fibres. If HHV-6 markers do not correlate with SFN severity → ISR-DRG mechanism not supported.
Limitation: The post-mortem HHV-6 DRG finding is from n=3 ME/CFS patients (Kasimir et al. 2022). No study has measured ISR markers specifically in DRG neurons or DRG-innervated skin in ME/CFS. ATF4 IHC in skin biopsy is not a validated clinical method.
HHV-6 reactivation has been confirmed in multiple brain regions in ME/CFS post-mortem tissue, including the choroid plexus, hippocampus, and amygdala (Kasimir et al. 2022). Brainstem nuclei involved in autonomic regulation — notably the nucleus tractus solitarius (NTS) and dorsal motor nucleus of the vagus — were not specifically examined in that study but are neurotropic targets of herpesviruses. If HHV-6 reactivation in brainstem nuclei activates ISR via miR-aU14–DRP1 (Hennig et al. 2022), local energy failure in autonomic regulatory circuits could produce the heart rate variability abnormalities, orthostatic intolerance, and autonomic dysregulation documented in ME/CFS without requiring peripheral nerve damage.
Research question: Does post-mortem brainstem tissue from ME/CFS patients show HHV-6 miR-aU14, ISR markers (phospho-eIF2α, ATF4), or mitochondrial fragmentation signatures in autonomic nuclei? Would HRV abnormalities correlate with brainstem rather than peripheral autonomic markers in living patients?
1.6 Visceral versus Somatic Small Fiber Involvement
The small fiber literature in ME/CFS has focused almost entirely on somatic fibers accessible by skin biopsy. A 2026 Long COVID study introduces a complementary — and partly divergent — picture from the visceral compartment. Acanfora et al. found selective cholinergic (VIP-positive) denervation of the gastric mucosa in Long COVID patients while intraepidermal (skin) nerve fiber density was preserved (Acanfora et al. 2026). This is the mirror image of the classic ME/CFS skin-biopsy finding, where somatic IENFD is reduced in ~31–49% of patients (Joseph et al. 2021) (Grayston et al. 2019), and where the non-length-dependent pattern documented by Azcue et al. (Azcue et al. 2023) also involves cutaneous fibers.
Acanfora et al. report selective visceral cholinergic denervation with preserved skin innervation in Long COVID (Acanfora et al. 2026), whereas Oaklander/Joseph et al. (Joseph et al. 2021) and Azcue et al. (Azcue et al. 2023) document somatic small fiber loss in ME/CFS. These evidence bases are not symmetric: the Acanfora finding is a single unreplicated study (\(n=12\), dyspeptic controls), while ME/CFS somatic SFN is supported by multiple independent cohorts and meta-analysis (Peripheral Nervous System); the apparent discrepancy may reflect the different evidence bases and the different tissues sampled rather than a genuine biological divergence, and remains an open question. Three explanations are compatible with current data: (a) Long COVID and ME/CFS are different diseases with different fiber-tropism; (b) they represent different stages of one process (visceral-first, somatic-later, or vice versa); or (c) the difference is methodological — gastric mucosal biopsy and lower-leg skin biopsy sample anatomically and functionally distinct fiber populations and cannot be directly compared. Acanfora’s small dyspeptic-control sample and the absence of matched skin-versus-mucosa sampling within the same ME/CFS cohort prevent resolution.
Research question: In a single ME/CFS cohort, do paired gastric-mucosal and skin biopsies reveal concordant or discordant small fiber loss? Does the visceral-versus-somatic ratio differ systematically between Long COVID and non-COVID ME/CFS, and does it track disease duration? Each explanation makes a discriminating prediction: concordant loss in most patients would rule out the pure methodological-artifact account (c); a visceral:somatic ratio that shifts monotonically with disease duration would support the single-process staging account (b) over the different-diseases account (a); and a stable, condition-specific ratio (visceral in Long COVID, somatic in non-COVID ME/CFS) that does not track duration would support (a).
Consequence: Whether the nerve damage in these conditions hits gut/autonomic nerves, skin/sensory nerves, or both determines which tests can detect it and which patients a given biopsy would miss — a skin biopsy could read “normal” in someone whose vagal nerves are actually damaged, so settling this would refine how researchers look for small fiber neuropathy in post-viral illness. This is a research proposition, not a current clinical recommendation: gastric mucosal nerve biopsy has no validated diagnostic role in ME/CFS or post-viral SFN outside research protocols.
2 Nerve Conduction Studies
2.1 Electrophysiological Findings
Standard nerve conduction studies (NCS) assess large myelinated fiber function and are typically normal in ME/CFS, consistent with selective small fiber involvement. However, some studies report:
- Subtle prolongation of distal latencies
- Reduced compound muscle action potential amplitudes
- Abnormal F-wave parameters
- Changes suggesting subclinical demyelination
2.2 Implications
The contrast between abnormal small fiber findings and relatively preserved large fiber function suggests:
- Selective vulnerability of small fibers to ME/CFS pathophysiology
- Potential autoimmune targeting of specific nerve fiber populations
- Metabolic or oxidative stress preferentially affecting unmyelinated fibers
- Different pathophysiology from typical diabetic or inflammatory neuropathies
3 Treatment of Small Fiber Neuropathy
The treatment guidance below is provided for clinical context within a pathophysiology chapter. All medications listed are prescription-only (several off-label in ME/CFS). Prescribers should consult current neuropathic pain guidelines (e.g. Finnerup et al. 2015 (Finnerup et al. 2015)) and the patient’s full medication list before initiation. This is not a substitute for individualised clinical assessment.
Management of SFN in ME/CFS requires addressing both symptomatic relief and underlying mechanisms. Treatment strategies must be adapted for ME/CFS-specific considerations including medication sensitivity and post-exertional malaise.
3.1 First-Line Neuropathic Pain Medications
Gabapentinoids. Gabapentin and pregabalin remain first-line treatments for neuropathic pain based on NeuPSIG guidelines (Finnerup et al. 2015). Dosing recommendations below derive from these guidelines and clinical experience; individual titration is essential:
- Gabapentin: Start 100–300 mg at bedtime; titrate slowly to 900–3600 mg/day in divided doses
- Pregabalin: Start 25–75 mg at bedtime; titrate to 150–600 mg/day in divided doses
- Mechanism: Bind alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release
- Benefits: Also improve sleep quality and may reduce central sensitization
- ME/CFS considerations: Start at lower doses due to common medication sensitivity; sedation may help or hinder depending on individual sleep patterns
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs). Duloxetine has FDA approval for diabetic peripheral neuropathy (Finnerup et al. 2015):
- Duloxetine: Start 20–30 mg daily; target 60 mg daily (range 30–120 mg)
- Venlafaxine: Alternative SNRI; 150–225 mg/day extended-release
- Mechanism: Enhance descending pain inhibition pathways via norepinephrine and serotonin
- Additional benefits: May help comorbid depression and fatigue in some patients
- Cautions: Discontinuation syndrome with abrupt cessation; may increase blood pressure
Tricyclic Antidepressants. Low-dose tricyclics provide analgesic effects independent of antidepressant action:
- Amitriptyline: Start 10 mg at bedtime; titrate to 25–75 mg (lower than antidepressant doses)
- Nortriptyline: Less sedating alternative; 10–75 mg at bedtime
- Mechanism: Block norepinephrine reuptake, sodium channels, and NMDA receptors
- Benefits: Improve sleep architecture; long clinical experience
- Cautions: Anticholinergic effects (dry mouth, constipation, urinary retention); cardiac effects at higher doses; morning sedation
3.2 Topical Treatments
Topical agents provide targeted relief with minimal systemic effects—particularly valuable in medication-sensitive ME/CFS patients:
Lidocaine.
- 5% lidocaine patches: Apply to painful areas for up to 12 hours daily
- Mechanism: Blocks sodium channels in peripheral nerves, reducing ectopic firing
- Advantages: Minimal systemic absorption; can be cut to size; well-tolerated
- Limitations: Localized effect only; works best for focal pain
Capsaicin.
- Low-concentration cream (0.025–0.075%): Apply 3–4 times daily
- High-concentration patch (8%): Single application by healthcare provider; effects last 3 months
- Mechanism: Depletes substance P from peripheral nerve endings; defunctionalizes TRPV1-expressing nociceptors. TRPV1 is sensitized by prostaglandins via EP1 and IP receptors (Moriyama et al. 2005) and by its own activation via a COX2 feed-forward loop (Li et al. 2021), making chronic sensitization self-sustaining without repeated external triggers; capsaicin desensitization interrupts this loop
- Cautions: Initial burning sensation (usually diminishes with regular use); avoid mucous membranes and eyes
3.3 Treatment of Underlying Causes
Autoimmune SFN. When SFN has an autoimmune etiology (suggested by anti-ganglioside or anti-sodium channel antibodies), immunomodulation may be beneficial (Oaklander and Nolano 2019):
- IVIG: 0.4 g/kg/day for 5 days, then monthly maintenance; case series evidence (low certainty) suggests improvement in pain and autonomic symptoms in autoimmune SFN, though RCT data are lacking (Liu et al. 2018)
- Corticosteroids: Short courses for acute flares; long-term use limited by side effects
- Other immunomodulators: Rituximab, azathioprine, mycophenolate in refractory cases
- ME/CFS relevance: Given autoimmune hypotheses in ME/CFS, autoimmune SFN testing should be considered in patients with prominent neuropathic features
SFN prevalence estimates in ME/CFS (30–60%) derive largely from fibromyalgia cohorts with assumed overlap rather than ME/CFS-specific studies. Key data gaps:
- The most-cited prevalence data (Oaklander 2013, Grayston 2019 meta-analysis) studied fibromyalgia patients, not ME/CFS cohorts selected by ME/CFS diagnostic criteria.
- No large-scale study has determined IENFD in a well-characterised ME/CFS cohort with appropriate controls.
- Treatment recommendations (alpha-lipoic acid, acetyl-L-carnitine, IVIG for autoimmune SFN) are extrapolated from diabetic neuropathy or case series; none have been tested in ME/CFS-specific trials.
- The causal relationship between SFN and ME/CFS symptoms is unestablished—SFN may be an independent comorbidity rather than a mechanistic contributor.
Metabolic and Nutritional Support. Several supplements may support nerve regeneration. Note that evidence derives primarily from diabetic neuropathy populations; efficacy in ME/CFS-associated SFN has not been specifically studied:
- Alpha-lipoic acid: 600–1800 mg daily; demonstrated efficacy in diabetic neuropathy RCTs (Ziegler et al. 2006); antioxidant and mitochondrial cofactor
- Acetyl-L-carnitine: 1500–3000 mg daily; supports neuronal energy metabolism; RCT evidence in diabetic neuropathy showing improved pain and nerve regeneration (Sima et al. 2005)
- B vitamins: B12 (methylcobalamin 1000–5000 mcg), B6 (avoid excess >100 mg/day, which can cause neuropathy), B1 (benfotiamine 300–600 mg)
- Mechanism: Support mitochondrial function, reduce oxidative stress, provide nerve membrane substrates
While B6 deficiency can cause neuropathy, excess pyridoxine supplementation (typically >200 mg/day chronically) can paradoxically cause a sensory neuropathy. Patients should not exceed 100 mg/day without medical supervision, and B6 levels should be checked if neuropathy worsens with supplementation.
3.4 ME/CFS-Specific Considerations
Treatment of SFN in ME/CFS requires adaptation for this population:
- Start low, go slow: Begin at 25–50% of typical starting doses due to medication sensitivity
- Single changes: Add or adjust one medication at a time to identify responses
- Sedation balance: Sedating medications (gabapentin, amitriptyline) may help sleep but worsen daytime fatigue
- Autonomic effects: Many neuropathic pain medications affect autonomic function; monitor orthostatic symptoms
- PEM awareness: Exercise-based therapies sometimes recommended for neuropathy are contraindicated in ME/CFS due to PEM risk
- Topical preference: Consider topical agents first given lower systemic burden
3.5 Treatment Algorithm
The following algorithm represents a proposed approach synthesized from NeuPSIG guidelines (Finnerup et al. 2015) and clinical experience with ME/CFS patients. It is not a validated clinical guideline:
- Diagnosis confirmation: Skin biopsy for IENFD; autonomic testing; screen for treatable causes (diabetes, B12 deficiency, autoantibodies)
- Address underlying causes: Treat autoimmune SFN with immunomodulation; correct nutritional deficiencies
- First-line symptomatic: Topical lidocaine for focal pain; low-dose gabapentinoid or TCA at bedtime
- Second-line: Add SNRI if inadequate response; consider combination therapy (e.g., gabapentinoid + TCA)
- Adjunctive support: Alpha-lipoic acid, acetyl-L-carnitine for neuroprotection (extrapolated from diabetic neuropathy evidence)
- Refractory cases: Pain medicine referral; interventional options; IVIG trial if autoimmune markers present
Can small fiber neuropathy in ME/CFS patients be reversed with appropriate treatment? Case reports suggest IENFD can normalize after treating underlying conditions (e.g., autoimmune SFN with IVIG, diabetic SFN with glucose control). If ME/CFS-associated SFN has an autoimmune or inflammatory basis, early immunomodulation might prevent permanent nerve damage. Longitudinal studies with serial skin biopsies in treated patients would clarify whether nerve regeneration is achievable.